<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ATTR_Amyloidosis - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>ATTR_Amyloidosis</span>
        </nav>

        <header class="page-header">
            <h1>ATTR_Amyloidosis</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0007100" target="_blank">
                        MONDO:0007100
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Amyloidosis</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Neuromuscular Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Cardiomyopathy</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">13</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">nervous system disorder</span>
                    
                    <span class="tag tag-classification">cardiovascular disorder</span>
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        ATTRm (hereditary)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by mutations in the TTR gene, leading to misfolded transthyretin proteins and amyloid deposits in various tissues.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25604431" target="_blank">PMID:25604431</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to..."</div>
                
                
                <div class="evidence-explanation">The literature clearly states that mutations in the TTR gene lead to the misfolding of transthyretin proteins, which then aggregate into amyloid fibrils, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34518987" target="_blank">PMID:34518987</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Heritable cardiac amyloidosis (CA) ... results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM)."</div>
                
                
                <div class="evidence-explanation">The literature confirms that hereditary cardiac amyloidosis results from the misfolding and accumulation of transthyretin due to mutations in the TTR gene.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30486687" target="_blank">PMID:30486687</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis, in which the disease is caused by mutant transthyretin (TTR)."</div>
                
                
                <div class="evidence-explanation">The literature supports that hereditary ATTRm amyloidosis is caused by mutations in the TTR gene, which leads to the disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        ATTRwt (wild-type/senile)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Occurs without mutations in the TTR gene, commonly affecting older individuals, with amyloid deposits primarily in the heart.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31731233" target="_blank">PMID:31731233</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Wild-type ATTR amyloidosis (ATTR-wt) is characterized by the accumulation of amyloid in the heart, leading to fatal heart failure and arrhythmia."</div>
                
                
                <div class="evidence-explanation">The study confirms that ATTR-wt occurs without mutations in the TTR gene and primarily affects the heart in older individuals.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26048914" target="_blank">PMID:26048914</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The non-hereditary form (ATTRwt) is caused by native or wild-type TTR and was previously referred to as senile systemic amyloidosis. ... The predominant effect of ATTRwt amyloidosis is on the heart"</div>
                
                
                <div class="evidence-explanation">The literature supports that ATTRwt occurs without mutations in the TTR gene and primarily affects the heart, commonly in older individuals.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34390072" target="_blank">PMID:34390072</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cardiac ATTR deposition occurred after age 75 years and increased in an age-dependent manner."</div>
                
                
                <div class="evidence-explanation">The study confirms that ATTRwt affects older individuals and involves amyloid deposits in the heart.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TTR Tetramer Destabilization</div>
                
                <div class="item-desc">Mutations in the TTR gene or age-related changes destabilize the native tetrameric structure, leading to dissociation into monomers. This is the rate-limiting step enabling protein misfolding and aggregation.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein tetramerization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051289" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        protein folding
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006457" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        extracellular space
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005615" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        blood plasma
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001969" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34884963" target="_blank">PMID:34884963</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Transthyretin (TTR) amyloidogenesis involves the formation, aggregation, and deposition of amyloid fibrils from tetrameric TTR in different organs and tissues."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that TTR amyloidogenesis involves the formation and aggregation of amyloid fibrils, which supports the statement that mutations in the TTR gene result in the production of unstable transthyretin proteins that misfold and aggregate into amyloid fibrils.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35830843" target="_blank">PMID:35830843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Familial amyloid polyneuropathy is currently prevalent worldwide as the transthyretin (TTR) Val30Met mutation, and there are other types of mutations."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by mentioning that familial amyloid polyneuropathy is caused by mutations in the TTR gene, which is consistent with the production of unstable transthyretin proteins that misfold and aggregate.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38844302" target="_blank">PMID:38844302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hereditary transthyretin-related amyloidosis (hATTR) is the most common form of familial amyloidosis. It is an autosomal dominant disease caused by a pathogenic variant in the TTR gene."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by explaining that hereditary transthyretin-related amyloidosis is caused by pathogenic variants in the TTR gene.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Amyloid Fibril Formation</div>
                
                <div class="item-desc">Misfolded transthyretin monomers undergo nucleation and elongation to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans stabilize deposits and reduce clearance.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        amyloid fibril formation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043241" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        extracellular space
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005615" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        heart
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000948" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        peripheral nervous system
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000010" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31452023" target="_blank">PMID:31452023</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"fibrillar deposits in a several organs including the heart, kidney, liver, and peripheral nerves cause organ dysfunction and associated morbidity and mortality."</div>
                
                
                <div class="evidence-explanation">The reference supports that amyloid fibrils deposit in the heart, kidney, and peripheral nerves, but does not mention the gastrointestinal tract.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15126690" target="_blank">PMID:15126690</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is possible that a common factor in the amyloidogenesis process exists among the different forms; this common factor can involve changes produced by mutations in the three-dimensional structure of TTR, rendering it prone to deposition as amyloid."</div>
                
                
                <div class="evidence-explanation">The reference supports that misfolded transthyretin proteins form amyloid fibrils but does not specify all the tissues mentioned in the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34018852" target="_blank">PMID:34018852</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Age-related wild-type transthyretin amyloidosis (wtATTR) is characterized by systemic deposition of amyloidogenic fibrils of misfolded transthyretin (TTR) in the connective tissue of many organs. In the heart, this leads to cardiac dysfunction, which is a significant cause of age-related heart failure."</div>
                
                
                <div class="evidence-explanation">The reference supports that amyloid fibrils deposit in the heart and connective tissue, but does not mention the nerves, kidneys, or gastrointestinal tract.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress and Mitochondrial Dysfunction</div>
                
                <div class="item-desc">TTR oligomers and fibrils induce reactive oxygen species production and impair mitochondrial function in cardiomyocytes, contributing to contractile dysfunction and cell injury.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        mitochondrion organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007005" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        heart
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000948" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Calcium Homeostasis Disruption</div>
                
                <div class="item-desc">Amyloid deposits disrupt intracellular calcium handling in cardiomyocytes, impairing contractility and promoting arrhythmogenesis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        cardiomyocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        calcium ion homeostasis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0055074" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        heart
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000948" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Peripheral Nerve Degeneration</div>
                
                <div class="item-desc">Amyloid deposition in peripheral nerves causes axonal degeneration and demyelination, affecting sensory, motor, and autonomic functions.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        peripheral neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Schwann cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002573" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        axonogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007409" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        myelination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042552" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        peripheral nervous system
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000010" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Cardiac and Neurological Dysfunction&#39; (from &#39;Amyloid Fibril Formation&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Cardiomyopathy[&#34;Cardiomyopathy&#34;]
    Renal_Dysfunction[&#34;Renal Dysfunction&#34;]
    Peripheral_Nerve_Degeneration[&#34;Peripheral Nerve Degeneration&#34;]
    Amyloid_Fibril_Formation[&#34;Amyloid Fibril Formation&#34;]
    Sensory_Loss[&#34;Sensory Loss&#34;]
    Numbness_and_Tingling[&#34;Numbness and Tingling&#34;]
    Carpal_Tunnel_Syndrome[&#34;Carpal Tunnel Syndrome&#34;]
    Fatigue[&#34;Fatigue&#34;]
    TTR_Tetramer_Destabilization[&#34;TTR Tetramer Destabilization&#34;]
    Peripheral_Neuropathy[&#34;Peripheral Neuropathy&#34;]
    Autonomic_Dysfunction[&#34;Autonomic Dysfunction&#34;]
    Arrhythmias[&#34;Arrhythmias&#34;]
    Vitreous_Opacities[&#34;Vitreous Opacities&#34;]
    Heart_Failure[&#34;Heart Failure&#34;]
    Oxidative_Stress_and_Mitochondrial_Dysfunction[&#34;Oxidative Stress and Mitochondrial Dysfunction&#34;]
    Calcium_Homeostasis_Disruption[&#34;Calcium Homeostasis Disruption&#34;]
    Cardiac_and_Neurological_Dysfunction[&#34;Cardiac and Neurological Dysfunction&#34;]
    Orthostatic_Hypotension[&#34;Orthostatic Hypotension&#34;]
    Gastrointestinal_Symptoms[&#34;Gastrointestinal Symptoms&#34;]

    TTR_Tetramer_Destabilization --&gt; Amyloid_Fibril_Formation
    Amyloid_Fibril_Formation -.-&gt; Cardiac_and_Neurological_Dysfunction
    Amyloid_Fibril_Formation --&gt; Oxidative_Stress_and_Mitochondrial_Dysfunction
    Amyloid_Fibril_Formation --&gt; Calcium_Homeostasis_Disruption
    Amyloid_Fibril_Formation --&gt; Peripheral_Nerve_Degeneration
    Amyloid_Fibril_Formation --&gt; Cardiomyopathy
    Amyloid_Fibril_Formation --&gt; Peripheral_Neuropathy
    Amyloid_Fibril_Formation --&gt; Carpal_Tunnel_Syndrome
    Amyloid_Fibril_Formation --&gt; Gastrointestinal_Symptoms
    Amyloid_Fibril_Formation --&gt; Renal_Dysfunction
    Amyloid_Fibril_Formation --&gt; Vitreous_Opacities
    Oxidative_Stress_and_Mitochondrial_Dysfunction --&gt; Cardiomyopathy
    Oxidative_Stress_and_Mitochondrial_Dysfunction --&gt; Heart_Failure
    Calcium_Homeostasis_Disruption --&gt; Arrhythmias
    Calcium_Homeostasis_Disruption --&gt; Heart_Failure
    Peripheral_Nerve_Degeneration --&gt; Peripheral_Neuropathy
    Peripheral_Nerve_Degeneration --&gt; Sensory_Loss
    Peripheral_Nerve_Degeneration --&gt; Numbness_and_Tingling
    Peripheral_Nerve_Degeneration --&gt; Autonomic_Dysfunction
    Peripheral_Nerve_Degeneration --&gt; Orthostatic_Hypotension
    Peripheral_Nerve_Degeneration --&gt; Fatigue
    Peripheral_Neuropathy --&gt; Sensory_Loss
    Peripheral_Neuropathy --&gt; Numbness_and_Tingling
    Peripheral_Neuropathy --&gt; Autonomic_Dysfunction
    Cardiomyopathy --&gt; Heart_Failure
    Cardiomyopathy --&gt; Arrhythmias
    Cardiomyopathy --&gt; Orthostatic_Hypotension

    style Cardiomyopathy fill:#fef3c7
    style Renal_Dysfunction fill:#fef3c7
    style Peripheral_Nerve_Degeneration fill:#dbeafe
    style Amyloid_Fibril_Formation fill:#dbeafe
    style Sensory_Loss fill:#fef3c7
    style Numbness_and_Tingling fill:#fef3c7
    style Carpal_Tunnel_Syndrome fill:#fef3c7
    style Fatigue fill:#fef3c7
    style TTR_Tetramer_Destabilization fill:#dbeafe
    style Peripheral_Neuropathy fill:#fef3c7
    style Autonomic_Dysfunction fill:#fef3c7
    style Arrhythmias fill:#fef3c7
    style Vitreous_Opacities fill:#fef3c7
    style Heart_Failure fill:#fef3c7
    style Oxidative_Stress_and_Mitochondrial_Dysfunction fill:#dbeafe
    style Calcium_Homeostasis_Disruption fill:#dbeafe
    style Cardiac_and_Neurological_Dysfunction fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style Orthostatic_Hypotension fill:#fef3c7
    style Gastrointestinal_Symptoms fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">13</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Genitourinary<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Nervous System<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Constitutional<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Other<span class="pill-count">(2)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cardiomyopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001638" target="_blank">
                                Cardiomyopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001638)</span>
                        </span>
                        
                    </div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Heart Failure</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Arrhythmias</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Orthostatic Hypotension</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34694575" target="_blank">PMID:34694575</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The hereditary forms of ATTR have further come into importance with the availability of genetic testing and increased prevalence of certain mutations in African Americans."</div>
                
                
                <div class="evidence-explanation">The reference discusses the increased recognition and diagnosis of ATTR cardiac amyloidosis, supporting the statement that it is frequently diagnosed as a cardiovascular condition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35235819" target="_blank">PMID:35235819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by listing heart failure, arrhythmias, and autonomic dysfunction (which includes orthostatic hypotension) as common sequelae of cardiac amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38044190" target="_blank">PMID:38044190</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with TTRA had higher levels of ultrasensitive troponin I (TnI-US) and N-terminal brain natriuretic propeptide (NT-ProBNP); in electrocardiography (ECG) they presented a pseudo-infarction pattern more frequently as well as conduction disturbances."</div>
                
                
                <div class="evidence-explanation">The reference supports the frequent occurrence of cardiovascular manifestations in ATTR amyloidosis, including cardiomyopathy and arrhythmias.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Heart Failure
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001635" target="_blank">
                                Congestive heart failure
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001635)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Progressive infiltrative cardiomyopathy leading to diastolic and systolic dysfunction</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arrhythmias
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0011675" target="_blank">
                                Arrhythmia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0011675)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Atrial fibrillation, conduction abnormalities, and ventricular arrhythmias</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Orthostatic Hypotension
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001278" target="_blank">
                                Orthostatic hypotension
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001278)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Drop in blood pressure upon standing due to autonomic neuropathy</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Vitreous Opacities
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0007710" target="_blank">
                                Peripheral vitreous opacities
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0007710)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Can lead to visual impairment</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28085522" target="_blank">PMID:28085522</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We report on two elderly patients (an 80-year-old woman and an 83-year-old man) with progressive vitreous opacities (VOs) as the initial manifestation of hereditary transthyretin (ATTR Val30Met) carries, who had no evidence of systemic involvement or family history of amyloidosis and lived in..."</div>
                
                
                <div class="evidence-explanation">The reference provides evidence that vitreous opacities can be an initial manifestation in patients with hereditary transthyretin amyloidosis (ATTR Val30Met), supporting the statement that vitreous opacities occur occasionally in ATTR amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36129270" target="_blank">PMID:36129270</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"However, 3 patients (43%) had worsening vitreous opacities in both eyes, and 4 patients (57%) developed secondary open-angle glaucoma."</div>
                
                
                <div class="evidence-explanation">The reference indicates that vitreous opacities were observed and worsened in some patients with ATTR amyloidosis, supporting the statement that vitreous opacities can occur occasionally in ATTR amyloidosis and lead to visual impairment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Genitourinary
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Renal Dysfunction
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000083" target="_blank">
                                Renal insufficiency
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000083)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Due to amyloid deposition in the kidneys, can lead to proteinuria and renal failure</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22537653" target="_blank">PMID:22537653</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peripheral neuropathy and cardiomyopathy are broadly described, and insights into disease reveal that kidney impairment and proteinuria are also clinical features."</div>
                
                
                <div class="evidence-explanation">The reference confirms that renal dysfunction, including proteinuria, is a clinical feature of transthyretin amyloidosis (ATTR).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37997196" target="_blank">PMID:37997196</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy that commonly presents with concomitant chronic kidney disease."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by indicating that chronic kidney disease, which encompasses renal dysfunction, is commonly associated with transthyretin cardiac amyloidosis (ATTR-CA).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Peripheral Neuropathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0009830" target="_blank">
                                Peripheral neuropathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0009830)</span>
                        </span>
                        
                    </div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Sensory Loss</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Numbness and Tingling</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Autonomic Dysfunction</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23239211" target="_blank">PMID:23239211</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peripheral neuropathy is a common complication of many of the systemic amyloidoses."</div>
                
                
                <div class="evidence-explanation">The literature indicates that peripheral neuropathy is a common complication of amyloidoses, which includes ATTR amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35830843" target="_blank">PMID:35830843</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The clinical manifestations of this mutation involve mainly limb sensory or motor disorders or gastrointestinal symptoms or both, and the electrophysiological examination shows neurogenic damage."</div>
                
                
                <div class="evidence-explanation">This study indicates that peripheral neuropathy, including sensory and motor disorders, is a frequent manifestation in patients with the TTR Val30Leu mutation, a form of familial amyloid polyneuropathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31445300" target="_blank">PMID:31445300</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a rare, life-threatening disease, caused by point mutations in the transthyretin gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and..."</div>
                
                
                <div class="evidence-explanation">The literature confirms that hATTR amyloidosis frequently involves polyneuropathy, including sensory loss, numbness, tingling, and autonomic dysfunction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Sensory Loss
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003474" target="_blank">
                                Somatic sensory dysfunction
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003474)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Loss of sensation, particularly in extremities, due to peripheral nerve damage</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Numbness and Tingling
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003401" target="_blank">
                                Paresthesia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003401)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Paresthesias in hands and feet as early manifestation of neuropathy</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Autonomic Dysfunction
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012332" target="_blank">
                                Abnormal autonomic nervous system physiology
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012332)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Includes orthostatic hypotension, gastroparesis, bladder dysfunction</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fatigue
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                                Fatigue
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012378)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Can be severe and limit activities of daily living</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35144512" target="_blank">PMID:35144512</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients often reported problems with mobility, usual activities, pain/discomfort and anxiety/depression, but not with self-care."</div>
                
                
                <div class="evidence-explanation">The literature indicates that systemic amyloidosis, including ATTR, frequently impacts daily life and mobility, which can be associated with fatigue.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31445300" target="_blank">PMID:31445300</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy (including sensory, motor, and autonomic impairments) and cardiac dysfunction."</div>
                
                
                <div class="evidence-explanation">The literature describes ATTR amyloidosis as a multisystem disease, which can imply the presence of fatigue due to its systemic impact.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33609196" target="_blank">PMID:33609196</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Amyloid transthyretin (ATTR) amyloidosis is a clinically heterogeneous and fatal disease that results from deposition of insoluble amyloid fibrils in various organs and tissues, causing progressive loss of function."</div>
                
                
                <div class="evidence-explanation">The progressive loss of function in various organs and tissues can lead to severe fatigue, limiting activities of daily living.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Gastrointestinal Symptoms
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Include nausea, diarrhea, constipation, and weight loss</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25908211" target="_blank">PMID:25908211</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Gastrointestinal manifestations are common in hereditary ATTR amyloidosis and are important for the patients&#39; morbidity and mortality."</div>
                
                
                <div class="evidence-explanation">The study highlights that gastrointestinal manifestations are common in hereditary ATTR amyloidosis, supporting the statement that gastrointestinal symptoms are frequent in this condition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32176096" target="_blank">PMID:32176096</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Transthyretin amyloid (ATTR) amyloidosis is a rare systemic disorder characterized by amyloid deposits formed by misfolded monomers of the transthyretin. Gastrointestinal (GI) manifestations are common in ATTR amyloidosis; however, their pathogenesis is not fully elucidated."</div>
                
                
                <div class="evidence-explanation">This reference supports the frequency of gastrointestinal symptoms in ATTR amyloidosis, aligning with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37844979" target="_blank">PMID:37844979</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the early stages of amyloidosis, gastrointestinal (GI) symptoms are uncommon. We describe a rare case of hereditary transthyretin amyloidosis (ATTRv) with involvement of the heart, nervous system and GI tract."</div>
                
                
                <div class="evidence-explanation">Although it mentions that GI symptoms are uncommon in the early stages, it describes a case with significant GI involvement, supporting the statement about frequent GI symptoms in later stages.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Carpal Tunnel Syndrome
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Due to amyloid deposition in the wrist</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30404120" target="_blank">PMID:30404120</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"One cause for a carpal tunnel syndrome is transthyretin (ATTR) amyloid, which deposits in the carpal tunnel tissue."</div>
                
                
                <div class="evidence-explanation">The article states that ATTR amyloid deposits in the carpal tunnel tissue can cause carpal tunnel syndrome, supporting the statement that ATTR amyloidosis can occasionally cause this musculoskeletal condition.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33443391" target="_blank">PMID:33443391</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common orthopaedic manifestations of amyloidosis include carpal tunnel syndrome, trigger finger, spontaneous distal biceps tendon rupture, rotator cuff disease, and lumbar spinal stenosis."</div>
                
                
                <div class="evidence-explanation">The article mentions carpal tunnel syndrome as a common orthopedic manifestation of amyloidosis, supporting the statement that ATTR amyloidosis can occasionally cause this condition due to amyloid deposition in the wrist.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TTR
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38844302" target="_blank">PMID:38844302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"More than 140 TTR gene variants have been associated with hATTR, with the Val30Met variant representing the most common worldwide."</div>
                
                
                <div class="evidence-explanation">This reference supports the association of the Val30Met variant with ATTR amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24555660" target="_blank">PMID:24555660</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A previous study of the amyloidogenic transthyretin mutation TTRV30M in Northern Sweden&#39;s endemic area has shown a large variation in carrier frequency and penetrance of the trait within the area."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement about the variable frequency of the Val30Met variant by population.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36941075" target="_blank">PMID:36941075</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hereditary transthyretin amyloidosis (hATTR) is a rare autosomal dominant systemic disease with variable penetrance and heterogeneous clinical presentation."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement about the variable frequency of pathogenic variants by population.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    APCS
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Modifying Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CLU
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Modifying Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Tafamidis
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Helps stabilize transthyretin and prevent amyloid fibril formation.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25872787" target="_blank">PMID:25872787</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tafamidis treatment effectively achieved and maintained TTR stabilization and was well tolerated."</div>
                
                
                <div class="evidence-explanation">The study shows that tafamidis effectively stabilizes TTR, supporting the statement that it helps stabilize transthyretin.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31098895" target="_blank">PMID:31098895</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Tafamidis slowed deterioration of neurological function and maintained health-related quality of life in patients with early-stage ATTR-PN... TTR tetramers were stabilized in nearly all patients."</div>
                
                
                <div class="evidence-explanation">The evidence indicates that tafamidis stabilizes TTR tetramers, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26800456" target="_blank">PMID:26800456</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal became the first line anti-amyloid treatment in stage 1 TTR-FAP. Both drugs slow progression of the disease."</div>
                
                
                <div class="evidence-explanation">The study supports that tafamidis is effective in stabilizing TTR and preventing amyloid fibril formation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Patisiran
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Reduces production of transthyretin protein to decrease amyloid formation.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30480471" target="_blank">PMID:30480471</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patisiran is a novel RNA interference therapeutic that specifically reduces production of both wild-type and mutant transthyretin protein."</div>
                
                
                <div class="evidence-explanation">The abstract clearly states that patisiran reduces the production of transthyretin protein, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37599395" target="_blank">PMID:37599395</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv)."</div>
                
                
                <div class="evidence-explanation">The abstract mentions that patisiran, as an RNAi therapeutic, benefits patients with hereditary transthyretin amyloidosis, indicating its role in reducing transthyretin protein production.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31131842" target="_blank">PMID:31131842</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Onpattro, also commonly known as patisiran, is a small interfering RNA (siRNA) molecule packaged within a lipid nanoparticle and is transported into the cell to target transthyretin gene (TTR) messenger mRNA (mRNA) by attaching to its complementary sequence. The target mRNA is degraded and both..."</div>
                
                
                <div class="evidence-explanation">The abstract explicitly states that patisiran targets and degrades transthyretin mRNA, thus reducing the production of transthyretin protein.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Inotersen
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Reduces TTR protein production to limit amyloid accumulation.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30561247" target="_blank">PMID:30561247</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation antisense oligonucleotide (ASO) specific for TTR that inhibits production of TTR by the liver."</div>
                
                
                <div class="evidence-explanation">The reference confirms that Inotersen reduces TTR protein production by inhibiting its production in the liver, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37599395" target="_blank">PMID:37599395</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"&#39;Aims: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran and inotersen have been shown to benefit neurologic disease course and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv)."</div>
                
                
                <div class="evidence-explanation">The reference supports that Inotersen is used to treat ATTR amyloidosis and implies its role in reducing TTR protein production.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31343345" target="_blank">PMID:31343345</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Inotersen treatment for ATTR amyloidosis."</div>
                
                
                <div class="evidence-explanation">This reference title directly states that Inotersen is used for the treatment of ATTR amyloidosis, implying its role in reducing TTR protein production.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver Transplant
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Considered for hereditary cases to reduce production of mutant TTR.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25482846" target="_blank">PMID:25482846</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Orthotopic liver transplantation (OLT) was implemented as the inaugural disease-modifying therapy because the liver produces the circulating unstable TTR."</div>
                
                
                <div class="evidence-explanation">The literature supports liver transplantation as a therapy to address the production of unstable TTR in hereditary ATTR amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23797140" target="_blank">PMID:23797140</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Therefore, liver transplantation has become widely accepted as the ultimate curative treatment of this disease in order to prevent the ultimately fatal outcome and ameliorate disabling symptoms."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of liver transplantation to reduce the production of mutant TTR in hereditary cases of ATTR amyloidosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Heart Transplant
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May be necessary for those with severe cardiomyopathy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32304420" target="_blank">PMID:32304420</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"However, the end-stage heart failure is common and HTx could be offered to selected patients, especially if affected by light chain cardiac amyloidosis, to allow to perform the autologous stem cell transplantation after the cardiac transplant."</div>
                
                
                <div class="evidence-explanation">The statement is supported as heart transplantation is mentioned as a treatment for end-stage heart failure in patients with cardiac amyloidosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33621542" target="_blank">PMID:33621542</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Orthotopic heart transplantation (OHT) remains the definitive treatment for patients with end stage heart failure."</div>
                
                
                <div class="evidence-explanation">The statement is supported as orthotopic heart transplantation is identified as a definitive treatment for end-stage heart failure in amyloid cardiomyopathy patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34922822" target="_blank">PMID:34922822</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Heart Transplantation (HT) is a rational therapy for advanced transthyretin cardiac amyloidosis (ATTR-CA)..."</div>
                
                
                <div class="evidence-explanation">The statement is supported as heart transplantation is described as a rational therapy for advanced transthyretin cardiac amyloidosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Symptomatic treatment for neuropathy, heart failure, and gastrointestinal issues.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33099432" target="_blank">PMID:33099432</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Supportive care manages the symptoms of organ involvement and the side effects of treatment."</div>
                
                
                <div class="evidence-explanation">The reference indicates that supportive care is used to manage the symptoms of organ involvement, which can include neuropathy, heart failure, and gastrointestinal issues.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35235819" target="_blank">PMID:35235819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial and ventricular arrhythmias, conduction disturbances, and profound autonomic dysfunction."</div>
                
                
                <div class="evidence-explanation">The reference highlights the management of cardiovascular symptoms in cardiac amyloidosis, which is part of supportive care.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35104443" target="_blank">PMID:35104443</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Systemic amyloidosis is characterized by extracellular deposition of insoluble fibrillar proteins in multiple tissues... The 2 most common forms, light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy and, rarely, myopathy."</div>
                
                
                <div class="evidence-explanation">The reference discusses the management of neuromuscular complications, including neuropathy, which is part of supportive care.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">None Applicable</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21463231" target="_blank">PMID:21463231</a>
                    </span>
                    
                    <span class="evidence-support support-WRONG_STATEMENT">WRONG_STATEMENT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Transthyretin (TTR) Val30Met-associated familial amyloid polyneuropathy (FAP ATTR Val30Met) is the most common form of FAP."</div>
                
                
                <div class="evidence-explanation">The statement that ATTR amyloidosis is &#39;None Applicable&#39; is incorrect as it is associated with specific conditions such as familial amyloid polyneuropathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37907148" target="_blank">PMID:37907148</a>
                    </span>
                    
                    <span class="evidence-support support-WRONG_STATEMENT">WRONG_STATEMENT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CARS (Cardiac Amyloidosis Registry Study) is a multicenter registry established in 2019 that includes patients with transthyretin (ATTR, wild-type and variant) and light chain (AL) cardiac amyloidosis (CA)."</div>
                
                
                <div class="evidence-explanation">The statement &#39;None Applicable&#39; is incorrect because ATTR amyloidosis is a recognized condition included in the Cardiac Amyloidosis Registry Study.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Serum Transthyretin Levels
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Abnormal (low))</span>
                    
                </div>
                
                <div class="item-desc">Context: Diagnostic indicator</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32356182" target="_blank">PMID:32356182</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lower levels of transthyretin and retinol binding protein-4 have been demonstrated in patients with pathogenic mutations of transthyretin either with or without clinical disease."</div>
                
                
                <div class="evidence-explanation">The literature indicates that lower levels of transthyretin are associated with transthyretin amyloidosis, supporting the statement that abnormal (low) serum transthyretin levels can be a diagnostic indicator.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Amyloid P Component
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12394612" target="_blank">PMID:12394612</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Radiolabelled serum amyloid P component scintigraphy is a non-invasive and quantitative method for imaging amyloid deposits, which produces diagnostic images in most patients with systemic amyloidosis, and can be used repeatedly to monitor the course of the disease."</div>
                
                
                <div class="evidence-explanation">The reference indicates that serum amyloid P component scintigraphy can be used to monitor the course of systemic amyloidosis, but it does not specify whether the levels of amyloid P component are elevated in ATTR amyloidosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: ATTR_Amyloidosis
category: Genetic
parents:
- Amyloidosis
- Neuromuscular Disorder
- Cardiomyopathy
has_subtypes:
- name: ATTRm (hereditary)
  description: Caused by mutations in the TTR gene, leading to misfolded transthyretin
    proteins and amyloid deposits in various tissues.
  evidence:
  - reference: PMID:25604431
    supports: SUPPORT
    snippet: Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function
      disease characterised by extracellular deposition of amyloid fibrils composed
      of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone
      to dissociate from its native tetramer to monomer, and to then misfold and aggregate
      into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis.
    explanation: The literature clearly states that mutations in the TTR gene lead
      to the misfolding of transthyretin proteins, which then aggregate into amyloid
      fibrils, supporting the statement.
  - reference: PMID:34518987
    supports: SUPPORT
    snippet: Heritable cardiac amyloidosis (CA) ... results from the accumulation
      of the misfolded protein transthyretin within the myocardium, resulting in amyloid
      transthyretin-associated cardiomyopathy (ATTR-CM).
    explanation: The literature confirms that hereditary cardiac amyloidosis results
      from the misfolding and accumulation of transthyretin due to mutations in the
      TTR gene.
  - reference: PMID:30486687
    supports: SUPPORT
    snippet: Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial
      amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis,
      in which the disease is caused by mutant transthyretin (TTR).
    explanation: The literature supports that hereditary ATTRm amyloidosis is caused
      by mutations in the TTR gene, which leads to the disease.
  - reference: PMID:22094129
    supports: SUPPORT
    snippet: Familial amyloid polyneuropathies (FAPs) are a group of life-threatening
      multisystem disorders transmitted as an autosomal dominant trait. Nerve lesions
      are induced by deposits of amyloid fibrils, most commonly due to mutated transthyretin
      (TTR).
    explanation: The literature confirms that familial amyloid polyneuropathies, a
      form of hereditary ATTR amyloidosis, are caused by mutated TTR leading to amyloid
      deposits.
- name: ATTRwt (wild-type/senile)
  description: Occurs without mutations in the TTR gene, commonly affecting older
    individuals, with amyloid deposits primarily in the heart.
  evidence:
  - reference: PMID:31731233
    supports: SUPPORT
    snippet: Wild-type ATTR amyloidosis (ATTR-wt) is characterized by the accumulation
      of amyloid in the heart, leading to fatal heart failure and arrhythmia.
    explanation: The study confirms that ATTR-wt occurs without mutations in the TTR
      gene and primarily affects the heart in older individuals.
  - reference: PMID:26048914
    supports: SUPPORT
    snippet: The non-hereditary form (ATTRwt) is caused by native or wild-type TTR
      and was previously referred to as senile systemic amyloidosis. ... The predominant
      effect of ATTRwt amyloidosis is on the heart
    explanation: The literature supports that ATTRwt occurs without mutations in the
      TTR gene and primarily affects the heart, commonly in older individuals.
  - reference: PMID:34390072
    supports: SUPPORT
    snippet: Cardiac ATTR deposition occurred after age 75 years and increased in
      an age-dependent manner.
    explanation: The study confirms that ATTRwt affects older individuals and involves
      amyloid deposits in the heart.
  - reference: PMID:32441155
    supports: SUPPORT
    snippet: Tissue accumulation of misfolded transthyretin (TTR) may occur because
      of TTR gene mutations (variant amyloid TTR amyloidosis, ATTRv), or as an age-related
      phenomenon (wild-type ATTR, ATTRwt).
    explanation: The literature supports that ATTRwt occurs without TTR gene mutations
      and is age-related, affecting the heart.
  - reference: PMID:28329248
    supports: SUPPORT
    snippet: Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease
      predominantly of elderly male, characterized by concentric LV hypertrophy, preserved
      LVEF, and low QRS voltages.
    explanation: The study supports that ATTRwt commonly affects older individuals
      and involves the heart.
prevalence:
- population: Global
  percentage: Rare
  evidence:
  - reference: PMID:35297258
    supports: SUPPORT
    snippet: Amyloidosis is a systemic disease characterized by extracellular deposition
      of amyloid protein, most commonly in the heart and kidney. Hepatic amyloidosis
      is a rare form of presentation that ranges from mild hepatomegaly and altered
      liver biochemical tests to acute liver failure.
    explanation: The reference indicates that amyloidosis, including ATTR amyloidosis,
      is rare, supporting the statement that ATTR amyloidosis is rare globally.
  - reference: PMID:37907148
    supports: SUPPORT
    snippet: CARS aims to describe the natural history of CA with attention to clinical
      and diagnostic variables at the time of diagnosis, real-world treatment patterns,
      and associated outcomes of patients in a diverse cohort that is more representative
      of the at-risk population than that described in CA clinical trials.
    explanation: The reference discusses the CARS registry, which includes a diverse
      cohort of patients with cardiac amyloidosis, including ATTR amyloidosis, indicating
      that it is a condition under study due to its rarity and complexity.
progression:
- phase: Onset
  age_range: 30-70 (hereditary); 60-80 (wild-type)
  evidence:
  - reference: PMID:35717381
    supports: PARTIAL
    snippet: Symptomatic patients were predominantly male (71.4%) and had a mean ...
      age of symptom onset of 56.3 (17.8) years.
    explanation: The study provides data on the age of symptom onset for symptomatic
      patients with ATTR amyloidosis, indicating a mean age of onset within the provided
      range for hereditary cases. However, it does not specify the exact onset age
      range for wild-type cases.
  - reference: PMID:30199915
    supports: PARTIAL
    snippet: There is a significant increase in the number of patients with cardiac
      amyloidosis of the ATTR wild-type variety. These patients are often elderly
      males presenting with predominantly right sided heart failure.
    explanation: This reference suggests that ATTR wild-type amyloidosis commonly
      affects elderly males, but it does not provide a specific onset age range of
      60-80 years.
  - reference: PMID:31731233
    supports: PARTIAL
    snippet: The prevalence of ATTR-wt was 5.8% (32 of the 556), with the prevalence
      increasing as a function of age. We identified an ATTR-wt-specific morbidity
      rate of 12.3% for patients over 80 years of age, while the prevalence among
      individuals over 90 years of age was 34.9%.
    explanation: This study indicates that the prevalence of wild-type ATTR amyloidosis
      increases with age, particularly in those over 80 years. It supports the general
      notion that wild-type ATTR affects older individuals but does not provide a
      specific onset age range of 60-80 years.
  - reference: PMID:25586652
    supports: NO_EVIDENCE
    snippet: The aim of the study was to evaluate the clinical and genetic predictors
      of AA amyloidosis in patients with familial Mediterranean fever (FMF).
    explanation: This study focuses on AA amyloidosis in familial Mediterranean fever
      and does not provide information on the age of onset for ATTR amyloidosis.
pathophysiology:
- name: TTR Tetramer Destabilization
  description: Mutations in the TTR gene or age-related changes destabilize the native
    tetrameric structure, leading to dissociation into monomers. This is the rate-limiting
    step enabling protein misfolding and aggregation.
  biological_processes:
  - preferred_term: protein tetramerization
    term:
      id: GO:0051289
      label: protein homotetramerization
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  locations:
  - preferred_term: extracellular space
    term:
      id: GO:0005615
      label: extracellular space
  - preferred_term: blood plasma
    term:
      id: UBERON:0001969
      label: blood plasma
  evidence:
  - reference: PMID:34884963
    supports: SUPPORT
    snippet: Transthyretin (TTR) amyloidogenesis involves the formation, aggregation,
      and deposition of amyloid fibrils from tetrameric TTR in different organs and
      tissues.
    explanation: The abstract mentions that TTR amyloidogenesis involves the formation
      and aggregation of amyloid fibrils, which supports the statement that mutations
      in the TTR gene result in the production of unstable transthyretin proteins
      that misfold and aggregate into amyloid fibrils.
  - reference: PMID:35830843
    supports: SUPPORT
    snippet: Familial amyloid polyneuropathy is currently prevalent worldwide as the
      transthyretin (TTR) Val30Met mutation, and there are other types of mutations.
    explanation: This reference supports the statement by mentioning that familial
      amyloid polyneuropathy is caused by mutations in the TTR gene, which is consistent
      with the production of unstable transthyretin proteins that misfold and aggregate.
  - reference: PMID:38844302
    supports: SUPPORT
    snippet: Hereditary transthyretin-related amyloidosis (hATTR) is the most common
      form of familial amyloidosis. It is an autosomal dominant disease caused by
      a pathogenic variant in the TTR gene.
    explanation: This reference supports the statement by explaining that hereditary
      transthyretin-related amyloidosis is caused by pathogenic variants in the TTR
      gene.
  - reference: PMID:22471982
    supports: SUPPORT
    snippet: hereditary transthyretin (TTR) amyloidosis which is a genetically transmitted
      disease that results from a mutation in the gene encoding the plasma TTR protein.
    explanation: The abstract confirms that hereditary transthyretin amyloidosis results
      from mutations in the TTR gene, which aligns with the statement.
  - reference: PMID:29962408
    supports: SUPPORT
    snippet: Hereditary transthyretin (TTR)-related amyloidosis is caused by mutations
      in the TTR gene. The mutations destabilize the tetramer and/or monomer of TTR,
      and thus the stabilization of TTR is a key strategy for the treatment of TTR-related
      amyloidosis.
    explanation: This reference explicitly states that hereditary transthyretin-related
      amyloidosis is caused by mutations in the TTR gene that destabilize the protein,
      supporting the statement.
  downstream:
  - target: Amyloid Fibril Formation
    description: Tetramer dissociation exposes unstable monomers that misfold and aggregate into amyloid fibrils.
- name: Amyloid Fibril Formation
  description: Misfolded transthyretin monomers undergo nucleation and elongation
    to form cross-beta amyloid fibrils. Serum amyloid P component and proteoglycans
    stabilize deposits and reduce clearance.
  biological_processes:
  - preferred_term: amyloid fibril formation
    term:
      id: GO:0043241
      label: amyloid fibril formation
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: extracellular space
    term:
      id: GO:0005615
      label: extracellular space
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  downstream:
  - target: Cardiac and Neurological Dysfunction
    description: Extracellular deposition of misfolded transthyretin monomers as insoluble
      amyloid fibrils causes cardiomyopathy and polyneuropathy.
    evidence:
    - reference: PMID:40649158
      supports: SUPPORT
      snippet: Transthyretin-related (ATTR) amyloidosis is a progressive, multisystem
        disease caused by the extracellular deposition of misfolded transthyretin
        (TTR) monomers as insoluble amyloid fibrils. Clinical manifestations vary
        widely and may include cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN),
        or mixed phenotypes.
      explanation: This 2025 review explicitly states that misfolded TTR monomers
        cause both cardiomyopathy and polyneuropathy, establishing the causal link
        between amyloid deposition and organ dysfunction.
  - target: Oxidative Stress and Mitochondrial Dysfunction
    description: Amyloid oligomers and fibrils induce cardiomyocyte ROS generation and mitochondrial injury.
  - target: Calcium Homeostasis Disruption
    description: Amyloid infiltration perturbs calcium handling and electrical stability in cardiac myocytes.
  - target: Peripheral Nerve Degeneration
    description: Endoneurial amyloid deposition drives progressive axonal injury and demyelination.
  - target: Cardiomyopathy
    description: Cardiac amyloid infiltration stiffens myocardium and impairs systolic/diastolic performance.
  - target: Peripheral Neuropathy
    description: Amyloid toxicity in peripheral nerves produces length-dependent sensorimotor neuropathy.
  - target: Carpal Tunnel Syndrome
    description: Amyloid deposition in the transverse carpal ligament and flexor retinaculum compresses median nerve.
  - target: Gastrointestinal Symptoms
    description: Enteric autonomic neuropathy and tissue amyloid deposition impair motility and absorption.
  - target: Renal Dysfunction
    description: Renal interstitial and vascular amyloid deposition contributes to declining kidney function.
  - target: Vitreous Opacities
    description: Ocular transthyretin amyloid accumulation causes progressive vitreous clouding.
  evidence:
  - reference: PMID:31452023
    supports: PARTIAL
    snippet: fibrillar deposits in a several organs including the heart, kidney, liver,
      and peripheral nerves cause organ dysfunction and associated morbidity and mortality.
    explanation: The reference supports that amyloid fibrils deposit in the heart,
      kidney, and peripheral nerves, but does not mention the gastrointestinal tract.
  - reference: PMID:15126690
    supports: PARTIAL
    snippet: It is possible that a common factor in the amyloidogenesis process exists
      among the different forms; this common factor can involve changes produced by
      mutations in the three-dimensional structure of TTR, rendering it prone to deposition
      as amyloid.
    explanation: The reference supports that misfolded transthyretin proteins form
      amyloid fibrils but does not specify all the tissues mentioned in the statement.
  - reference: PMID:34018852
    supports: PARTIAL
    snippet: Age-related wild-type transthyretin amyloidosis (wtATTR) is characterized
      by systemic deposition of amyloidogenic fibrils of misfolded transthyretin (TTR)
      in the connective tissue of many organs. In the heart, this leads to cardiac
      dysfunction, which is a significant cause of age-related heart failure.
    explanation: The reference supports that amyloid fibrils deposit in the heart
      and connective tissue, but does not mention the nerves, kidneys, or gastrointestinal
      tract.
  - reference: PMID:34361762
    supports: PARTIAL
    snippet: Studies of nerve biopsy or cardiac autopsy specimens from patients with
      ATTR and AL amyloidoses show atrophy of cells near amyloid fibril aggregates.
    explanation: The reference supports that amyloid fibrils deposit in the nerves
      and heart but does not mention the kidneys or gastrointestinal tract.
- name: Oxidative Stress and Mitochondrial Dysfunction
  description: TTR oligomers and fibrils induce reactive oxygen species production
    and impair mitochondrial function in cardiomyocytes, contributing to contractile
    dysfunction and cell injury.
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Cardiomyopathy
    description: Oxidative mitochondrial injury reduces contractile reserve and accelerates myocardial dysfunction.
  - target: Heart Failure
    description: Progressive cardiomyocyte energy failure contributes to symptomatic heart failure.
- name: Calcium Homeostasis Disruption
  description: Amyloid deposits disrupt intracellular calcium handling in cardiomyocytes,
    impairing contractility and promoting arrhythmogenesis.
  biological_processes:
  - preferred_term: calcium ion homeostasis
    term:
      id: GO:0055074
      label: calcium ion homeostasis
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  downstream:
  - target: Arrhythmias
    description: Calcium-handling instability promotes atrial and ventricular rhythm disturbances.
  - target: Heart Failure
    description: Impaired excitation-contraction coupling worsens pump failure.
- name: Peripheral Nerve Degeneration
  description: Amyloid deposition in peripheral nerves causes axonal degeneration
    and demyelination, affecting sensory, motor, and autonomic functions.
  biological_processes:
  - preferred_term: axonogenesis
    term:
      id: GO:0007409
      label: axonogenesis
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
  cell_types:
  - preferred_term: peripheral neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  downstream:
  - target: Peripheral Neuropathy
    description: Axonal loss and demyelination manifest as progressive polyneuropathy.
  - target: Sensory Loss
    description: Sensory fiber degeneration causes distal loss of vibration and pain perception.
  - target: Numbness and Tingling
    description: Irritable and degenerating peripheral nerves produce paresthesias.
  - target: Autonomic Dysfunction
    description: Autonomic fiber involvement leads to widespread dysautonomia.
  - target: Orthostatic Hypotension
    description: Autonomic denervation of vascular tone control causes postural blood pressure drops.
  - target: Fatigue
    description: Combined neuromuscular and autonomic impairment contributes to chronic fatigue.
phenotypes:
- category: Neurologic
  name: Peripheral Neuropathy
  frequency: FREQUENT
  diagnostic: true
  sequelae:
  - target: Sensory Loss
  - target: Numbness and Tingling
  - target: Autonomic Dysfunction
  evidence:
  - reference: PMID:23239211
    supports: SUPPORT
    snippet: Peripheral neuropathy is a common complication of many of the systemic
      amyloidoses.
    explanation: The literature indicates that peripheral neuropathy is a common complication
      of amyloidoses, which includes ATTR amyloidosis.
  - reference: PMID:35830843
    supports: SUPPORT
    snippet: The clinical manifestations of this mutation involve mainly limb sensory
      or motor disorders or gastrointestinal symptoms or both, and the electrophysiological
      examination shows neurogenic damage.
    explanation: This study indicates that peripheral neuropathy, including sensory
      and motor disorders, is a frequent manifestation in patients with the TTR Val30Leu
      mutation, a form of familial amyloid polyneuropathy.
  - reference: PMID:31445300
    supports: SUPPORT
    snippet: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is
      a rare, life-threatening disease, caused by point mutations in the transthyretin
      gene. It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy
      (including sensory, motor, and autonomic impairments) and cardiac dysfunction.
    explanation: The literature confirms that hATTR amyloidosis frequently involves
      polyneuropathy, including sensory loss, numbness, tingling, and autonomic dysfunction.
  - reference: PMID:36504143
    supports: SUPPORT
    snippet: Autonomic dysfunction is a common complication of small-fiber neuropathy
      (SFN).
    explanation: This study suggests that autonomic dysfunction is a common complication
      in small-fiber neuropathy, which can be seen in conditions like amyloidosis.
  phenotype_term:
    preferred_term: Peripheral Neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
- category: Cardiovascular
  name: Cardiomyopathy
  frequency: FREQUENT
  diagnostic: true
  sequelae:
  - target: Heart Failure
  - target: Arrhythmias
  - target: Orthostatic Hypotension
  evidence:
  - reference: PMID:34694575
    supports: SUPPORT
    snippet: The hereditary forms of ATTR have further come into importance with the
      availability of genetic testing and increased prevalence of certain mutations
      in African Americans.
    explanation: The reference discusses the increased recognition and diagnosis of
      ATTR cardiac amyloidosis, supporting the statement that it is frequently diagnosed
      as a cardiovascular condition.
  - reference: PMID:35235819
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial
      and ventricular arrhythmias, conduction disturbances, and profound autonomic
      dysfunction.
    explanation: This reference supports the statement by listing heart failure, arrhythmias,
      and autonomic dysfunction (which includes orthostatic hypotension) as common
      sequelae of cardiac amyloidosis.
  - reference: PMID:38044190
    supports: SUPPORT
    snippet: Patients with TTRA had higher levels of ultrasensitive troponin I (TnI-US)
      and N-terminal brain natriuretic propeptide (NT-ProBNP); in electrocardiography
      (ECG) they presented a pseudo-infarction pattern more frequently as well as
      conduction disturbances.
    explanation: The reference supports the frequent occurrence of cardiovascular
      manifestations in ATTR amyloidosis, including cardiomyopathy and arrhythmias.
  - reference: PMID:29770800
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA) comprises a heterogeneous group of medical conditions
      affecting the myocardium. It presents with proteinaceous infiltration with variable
      degrees of severity, prevalence and evolution.
    explanation: This reference supports the statement by describing the involvement
      of the myocardium (cardiomyopathy) and the frequent occurrence of cardiovascular
      symptoms in cardiac amyloidosis.
  - reference: PMID:38844297
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA), usually caused by deposition of misfolded transthyretin
      or immunoglobulin light chains, is an increasingly recognized cause of heart
      failure burdened by a poor prognosis.
    explanation: This reference supports the statement by describing heart failure
      as a frequent sequela of ATTR amyloidosis.
  phenotype_term:
    preferred_term: Cardiomyopathy
    term:
      id: HP:0001638
      label: Cardiomyopathy
- category: Gastrointestinal
  name: Gastrointestinal Symptoms
  frequency: FREQUENT
  notes: Include nausea, diarrhea, constipation, and weight loss
  evidence:
  - reference: PMID:25908211
    supports: SUPPORT
    snippet: Gastrointestinal manifestations are common in hereditary ATTR amyloidosis
      and are important for the patients&#39; morbidity and mortality.
    explanation: The study highlights that gastrointestinal manifestations are common
      in hereditary ATTR amyloidosis, supporting the statement that gastrointestinal
      symptoms are frequent in this condition.
  - reference: PMID:32176096
    supports: SUPPORT
    snippet: Transthyretin amyloid (ATTR) amyloidosis is a rare systemic disorder
      characterized by amyloid deposits formed by misfolded monomers of the transthyretin.
      Gastrointestinal (GI) manifestations are common in ATTR amyloidosis; however,
      their pathogenesis is not fully elucidated.
    explanation: This reference supports the frequency of gastrointestinal symptoms
      in ATTR amyloidosis, aligning with the statement.
  - reference: PMID:37844979
    supports: SUPPORT
    snippet: In the early stages of amyloidosis, gastrointestinal (GI) symptoms are
      uncommon. We describe a rare case of hereditary transthyretin amyloidosis (ATTRv)
      with involvement of the heart, nervous system and GI tract.
    explanation: Although it mentions that GI symptoms are uncommon in the early stages,
      it describes a case with significant GI involvement, supporting the statement
      about frequent GI symptoms in later stages.
  - reference: PMID:8115892
    supports: PARTIAL
    snippet: Gastrointestinal symptoms included anorexia, macroglossia, intestinal
      pseudo-obstruction, and altered bowel habits.
    explanation: This reference mentions gastrointestinal symptoms but does not specifically
      focus on ATTR amyloidosis. It partially supports the statement by acknowledging
      the presence of GI symptoms in amyloidosis in general.
  - reference: PMID:6402969
    supports: NO_EVIDENCE
    snippet: Gastrointestinal symptoms such as vomiting, constipation, diarrhea, and
      fecal incontinence occur frequently in patients with diabetes mellitus.
    explanation: This reference is focused on diabetes mellitus and does not provide
      evidence related to ATTR amyloidosis.
- category: Ocular
  name: Vitreous Opacities
  frequency: OCCASIONAL
  notes: Can lead to visual impairment
  evidence:
  - reference: PMID:28085522
    supports: SUPPORT
    snippet: We report on two elderly patients (an 80-year-old woman and an 83-year-old
      man) with progressive vitreous opacities (VOs) as the initial manifestation
      of hereditary transthyretin (ATTR Val30Met) carries, who had no evidence of
      systemic involvement or family history of amyloidosis and lived in non-endemic
      areas.
    explanation: The reference provides evidence that vitreous opacities can be an
      initial manifestation in patients with hereditary transthyretin amyloidosis
      (ATTR Val30Met), supporting the statement that vitreous opacities occur occasionally
      in ATTR amyloidosis.
  - reference: PMID:36129270
    supports: SUPPORT
    snippet: However, 3 patients (43%) had worsening vitreous opacities in both eyes,
      and 4 patients (57%) developed secondary open-angle glaucoma.
    explanation: The reference indicates that vitreous opacities were observed and
      worsened in some patients with ATTR amyloidosis, supporting the statement that
      vitreous opacities can occur occasionally in ATTR amyloidosis and lead to visual
      impairment.
  phenotype_term:
    preferred_term: Vitreous Opacities
    term:
      id: HP:0007710
      label: Peripheral vitreous opacities
- category: Musculoskeletal
  frequency: OCCASIONAL
  name: Carpal Tunnel Syndrome
  notes: Due to amyloid deposition in the wrist
  evidence:
  - reference: PMID:30404120
    supports: SUPPORT
    snippet: One cause for a carpal tunnel syndrome is transthyretin (ATTR) amyloid,
      which deposits in the carpal tunnel tissue.
    explanation: The article states that ATTR amyloid deposits in the carpal tunnel
      tissue can cause carpal tunnel syndrome, supporting the statement that ATTR
      amyloidosis can occasionally cause this musculoskeletal condition.
  - reference: PMID:33443391
    supports: SUPPORT
    snippet: Common orthopaedic manifestations of amyloidosis include carpal tunnel
      syndrome, trigger finger, spontaneous distal biceps tendon rupture, rotator
      cuff disease, and lumbar spinal stenosis.
    explanation: The article mentions carpal tunnel syndrome as a common orthopedic
      manifestation of amyloidosis, supporting the statement that ATTR amyloidosis
      can occasionally cause this condition due to amyloid deposition in the wrist.
- category: Genitourinary
  frequency: OCCASIONAL
  name: Renal Dysfunction
  notes: Due to amyloid deposition in the kidneys, can lead to proteinuria and renal
    failure
  evidence:
  - reference: PMID:22537653
    supports: SUPPORT
    snippet: Peripheral neuropathy and cardiomyopathy are broadly described, and insights
      into disease reveal that kidney impairment and proteinuria are also clinical
      features.
    explanation: The reference confirms that renal dysfunction, including proteinuria,
      is a clinical feature of transthyretin amyloidosis (ATTR).
  - reference: PMID:37997196
    supports: SUPPORT
    snippet: Transthyretin cardiac amyloidosis (ATTR-CA) is an infiltrative cardiomyopathy
      that commonly presents with concomitant chronic kidney disease.
    explanation: The reference supports the statement by indicating that chronic kidney
      disease, which encompasses renal dysfunction, is commonly associated with transthyretin
      cardiac amyloidosis (ATTR-CA).
  phenotype_term:
    preferred_term: Renal insufficiency
    term:
      id: HP:0000083
      label: Renal insufficiency
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  notes: Can be severe and limit activities of daily living
  evidence:
  - reference: PMID:35144512
    supports: SUPPORT
    snippet: Patients often reported problems with mobility, usual activities, pain/discomfort
      and anxiety/depression, but not with self-care.
    explanation: The literature indicates that systemic amyloidosis, including ATTR,
      frequently impacts daily life and mobility, which can be associated with fatigue.
  - reference: PMID:31445300
    supports: SUPPORT
    snippet: It is a heterogeneous, multisystem disease with rapidly progressing polyneuropathy
      (including sensory, motor, and autonomic impairments) and cardiac dysfunction.
    explanation: The literature describes ATTR amyloidosis as a multisystem disease,
      which can imply the presence of fatigue due to its systemic impact.
  - reference: PMID:33609196
    supports: SUPPORT
    snippet: Amyloid transthyretin (ATTR) amyloidosis is a clinically heterogeneous
      and fatal disease that results from deposition of insoluble amyloid fibrils
      in various organs and tissues, causing progressive loss of function.
    explanation: The progressive loss of function in various organs and tissues can
      lead to severe fatigue, limiting activities of daily living.
  - reference: PMID:35128833
    supports: SUPPORT
    snippet: Amyloidosis is a severe and fatal systemic disease, characterized by
      an accumulation of amyloid fibrils in various tissues/organs, including nerves,
      kidneys, gastrointestinal tract, and heart.
    explanation: The systemic nature of ATTR amyloidosis affecting multiple organs
      can contribute to fatigue.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Neurologic
  name: Sensory Loss
  frequency: FREQUENT
  notes: Loss of sensation, particularly in extremities, due to peripheral nerve damage
  phenotype_term:
    preferred_term: Sensory loss
    term:
      id: HP:0003474
      label: Somatic sensory dysfunction
- category: Neurologic
  name: Numbness and Tingling
  frequency: FREQUENT
  notes: Paresthesias in hands and feet as early manifestation of neuropathy
  phenotype_term:
    preferred_term: Paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
- category: Neurologic
  name: Autonomic Dysfunction
  frequency: FREQUENT
  notes: Includes orthostatic hypotension, gastroparesis, bladder dysfunction
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
- category: Cardiovascular
  name: Heart Failure
  frequency: FREQUENT
  notes: Progressive infiltrative cardiomyopathy leading to diastolic and systolic
    dysfunction
  phenotype_term:
    preferred_term: Heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
- category: Cardiovascular
  name: Arrhythmias
  frequency: FREQUENT
  notes: Atrial fibrillation, conduction abnormalities, and ventricular arrhythmias
  phenotype_term:
    preferred_term: Cardiac arrhythmia
    term:
      id: HP:0011675
      label: Arrhythmia
- category: Cardiovascular
  name: Orthostatic Hypotension
  frequency: FREQUENT
  notes: Drop in blood pressure upon standing due to autonomic neuropathy
  phenotype_term:
    preferred_term: Orthostatic hypotension
    term:
      id: HP:0001278
      label: Orthostatic hypotension
biochemical:
- name: Serum Transthyretin Levels
  presence: Abnormal (low)
  context: Diagnostic indicator
  evidence:
  - reference: PMID:32356182
    supports: SUPPORT
    snippet: Lower levels of transthyretin and retinol binding protein-4 have been
      demonstrated in patients with pathogenic mutations of transthyretin either with
      or without clinical disease.
    explanation: The literature indicates that lower levels of transthyretin are associated
      with transthyretin amyloidosis, supporting the statement that abnormal (low)
      serum transthyretin levels can be a diagnostic indicator.
- name: Amyloid P Component
  presence: Elevated
  notes: May be used to monitor disease progression
  evidence:
  - reference: PMID:12394612
    supports: PARTIAL
    snippet: Radiolabelled serum amyloid P component scintigraphy is a non-invasive
      and quantitative method for imaging amyloid deposits, which produces diagnostic
      images in most patients with systemic amyloidosis, and can be used repeatedly
      to monitor the course of the disease.
    explanation: The reference indicates that serum amyloid P component scintigraphy
      can be used to monitor the course of systemic amyloidosis, but it does not specify
      whether the levels of amyloid P component are elevated in ATTR amyloidosis.
genetic:
- name: TTR
  association: Pathogenic Variants
  notes: Primary amyloid precursor gene encoding transthyretin, a liver-derived homotetrameric
    transport protein for thyroxine and retinol. Tetramer instability leads to monomer
    misfolding and amyloid fibril formation.
  examples:
  - Val30Met
  - Thr60Ala
  frequency: Variable by population
  evidence:
  - reference: PMID:38844302
    supports: SUPPORT
    snippet: More than 140 TTR gene variants have been associated with hATTR, with
      the Val30Met variant representing the most common worldwide.
    explanation: This reference supports the association of the Val30Met variant with
      ATTR amyloidosis.
  - reference: PMID:24555660
    supports: SUPPORT
    snippet: A previous study of the amyloidogenic transthyretin mutation TTRV30M
      in Northern Sweden&#39;s endemic area has shown a large variation in carrier frequency
      and penetrance of the trait within the area.
    explanation: This reference supports the statement about the variable frequency
      of the Val30Met variant by population.
  - reference: PMID:36941075
    supports: SUPPORT
    snippet: Hereditary transthyretin amyloidosis (hATTR) is a rare autosomal dominant
      systemic disease with variable penetrance and heterogeneous clinical presentation.
    explanation: This reference supports the statement about the variable frequency
      of pathogenic variants by population.
- name: APCS
  association: Modifying Factor
  notes: Encodes serum amyloid P component (SAP), a plasma protein that binds and
    stabilizes amyloid fibrils in deposits, reducing proteolytic clearance.
- name: CLU
  association: Modifying Factor
  notes: Encodes clusterin, an extracellular chaperone present in TTR deposits that
    modulates fibril localization and clearance.
diagnosis:
- name: Genetic Testing for TTR Mutations
  presence: Positive in hereditary cases
  evidence:
  - reference: PMID:31520266
    supports: SUPPORT
    snippet: Genetic screening allows for the early identification of asymptomatic
      TTR mutation carriers.
    explanation: The literature supports that genetic testing for TTR mutations is
      positive in hereditary cases of ATTR amyloidosis.
  - reference: PMID:34076545
    supports: SUPPORT
    snippet: The hereditary transthyretin amyloidosis (ATTRv amyloidosis) is an autosomal
      dominant genetic disease characterized by amyloid formation in different tissues
      due to pathogenic variants in the TTR gene.
    explanation: This reference supports that hereditary cases of ATTR amyloidosis
      involve pathogenic variants in the TTR gene, which can be identified through
      genetic testing.
  - reference: PMID:37725003
    supports: SUPPORT
    snippet: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is
      caused by mutations in the TTR gene, leading to misfolded monomers that aggregate
      generating amyloid fibrils.
    explanation: This reference supports that genetic testing for TTR mutations is
      relevant in hereditary cases of ATTR amyloidosis.
- name: Biopsy with Congo Red Staining
  presence: Positive for amyloid deposits
  evidence:
  - reference: PMID:16493520
    supports: SUPPORT
    snippet: Congo red staining according to Romh√°nyi (1971) is a highly specific
      and sensitive method for early microscopic recognition of amyloidosis.
    explanation: The reference confirms that Congo red staining is a specific and
      sensitive method for detecting amyloid deposits, supporting the statement.
  - reference: PMID:34637570
    supports: SUPPORT
    snippet: Congo red staining detected amyloid deposits in systemic organs, including
      the heart, lungs, liver, and kidneys.
    explanation: The reference notes the use of Congo red staining to detect amyloid
      deposits in various organs, supporting the statement.
  - reference: PMID:28598015
    supports: SUPPORT
    snippet: Congo red staining revealed brilliant red amyloid deposits confirmed
      by apple-green birefringence within dermal collagen, sweat glands, and arrector
      pili that engulfed axons.
    explanation: The reference describes the detection of amyloid deposits using Congo
      red staining, supporting the statement.
  - reference: PMID:33433320
    supports: SUPPORT
    snippet: Light microscopy revealed marked brick-red staining in 11 of 42 samples,
      6 moderate and 11 slight staining in the septum of cells, medium and small sized
      vessel, and apple green double refraction under polarized light microscopy.
    explanation: The reference confirms that Congo red staining is used to detect
      amyloid deposits in biopsy samples, supporting the statement.
- name: Cardiac MRI
  notes: May show characteristic patterns of amyloid deposition
  evidence:
  - reference: PMID:37553542
    supports: SUPPORT
    snippet: Cardiac amyloidosis shows a particularly characteristic contrast enhancement
      in cardiac MRI, which mostly begins in the inner (subendocardial) layers of
      the basal left ventricular (LV) wall and frequently appears to be circular in
      the cross-sectional view of the left ventricle.
    explanation: The literature confirms that cardiac MRI can show characteristic
      patterns of amyloid deposition in ATTR amyloidosis.
  - reference: PMID:28728692
    supports: SUPPORT
    snippet: Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE)
      and T1 mapping, is emerging as a reference standard for diagnosis and characterization
      of cardiac amyloidosis.
    explanation: The literature supports that cardiac MRI (CMR) can show characteristic
      patterns in ATTR amyloidosis.
- name: Nerve Conduction Studies
  notes: Useful for diagnosing peripheral neuropathy
  evidence:
  - reference: PMID:21463231
    supports: PARTIAL
    snippet: Nonspecific neuropathic features and slight abnormalities in cerebrospinal
      fluid protein levels and in electrophysiological indices related to nerve conduction
      led clinicians to initially suspect chronic inflammatory demyelinating polyneuropathy
      (CIDP) in some patients.
    explanation: The reference indicates that nerve conduction studies can show abnormalities
      in ATTR amyloidosis, but it does not explicitly state that they are useful for
      diagnosing peripheral neuropathy specifically in ATTR amyloidosis.
  - reference: PMID:37658177
    supports: PARTIAL
    snippet: Prioritized neuropathy/autonomic endpoints included a modified form of
      the Neuropathy Impairment Score (NIS + 7) and the Composite Autonomic Symptom
      Score (COMPASS-31), respectively.
    explanation: The reference mentions neuropathy endpoints but does not provide
      specific information on the utility of nerve conduction studies for diagnosing
      peripheral neuropathy in ATTR amyloidosis.
environmental:
- name: None Applicable
  evidence:
  - reference: PMID:21463231
    supports: WRONG_STATEMENT
    snippet: Transthyretin (TTR) Val30Met-associated familial amyloid polyneuropathy
      (FAP ATTR Val30Met) is the most common form of FAP.
    explanation: The statement that ATTR amyloidosis is &#39;None Applicable&#39; is incorrect
      as it is associated with specific conditions such as familial amyloid polyneuropathy.
  - reference: PMID:37907148
    supports: WRONG_STATEMENT
    snippet: CARS (Cardiac Amyloidosis Registry Study) is a multicenter registry established
      in 2019 that includes patients with transthyretin (ATTR, wild-type and variant)
      and light chain (AL) cardiac amyloidosis (CA).
    explanation: The statement &#39;None Applicable&#39; is incorrect because ATTR amyloidosis
      is a recognized condition included in the Cardiac Amyloidosis Registry Study.
treatments:
- name: Tafamidis
  role: TTR Stabilizer
  description: Helps stabilize transthyretin and prevent amyloid fibril formation.
  evidence:
  - reference: PMID:25872787
    supports: SUPPORT
    snippet: Tafamidis treatment effectively achieved and maintained TTR stabilization
      and was well tolerated.
    explanation: The study shows that tafamidis effectively stabilizes TTR, supporting
      the statement that it helps stabilize transthyretin.
  - reference: PMID:31098895
    supports: SUPPORT
    snippet: Tafamidis slowed deterioration of neurological function and maintained
      health-related quality of life in patients with early-stage ATTR-PN... TTR tetramers
      were stabilized in nearly all patients.
    explanation: The evidence indicates that tafamidis stabilizes TTR tetramers, supporting
      the statement.
  - reference: PMID:26800456
    supports: SUPPORT
    snippet: Due to the data on efficacy, tolerability, safety, tafamidis and diflunisal
      became the first line anti-amyloid treatment in stage 1 TTR-FAP. Both drugs
      slow progression of the disease.
    explanation: The study supports that tafamidis is effective in stabilizing TTR
      and preventing amyloid fibril formation.
  - reference: PMID:29962408
    supports: SUPPORT
    snippet: The mutations destabilize the tetramer and/or monomer of TTR, and thus
      the stabilization of TTR is a key strategy for the treatment of TTR-related
      amyloidosis.
    explanation: The review supports that stabilizing TTR is crucial, and tafamidis
      is one of the compounds that achieve this.
  - reference: PMID:34609369
    supports: SUPPORT
    snippet: Several TTR molecule stabilizers were developed successfully... Silencing
      the TTR gene using different strategies is flourishing.
    explanation: The article states that TTR stabilizers, including tafamidis, have
      been successfully developed, supporting the statement.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Patisiran
  role: RNA Interference
  description: Reduces production of transthyretin protein to decrease amyloid formation.
  evidence:
  - reference: PMID:30480471
    supports: SUPPORT
    snippet: Patisiran is a novel RNA interference therapeutic that specifically reduces
      production of both wild-type and mutant transthyretin protein.
    explanation: The abstract clearly states that patisiran reduces the production
      of transthyretin protein, which aligns with the statement.
  - reference: PMID:37599395
    supports: SUPPORT
    snippet: Novel ribonucleic acid interference (RNAi) therapeutics such as patisiran
      and inotersen have been shown to benefit neurologic disease course and quality
      of life in patients with hereditary transthyretin amyloidosis (ATTRv).
    explanation: The abstract mentions that patisiran, as an RNAi therapeutic, benefits
      patients with hereditary transthyretin amyloidosis, indicating its role in reducing
      transthyretin protein production.
  - reference: PMID:31131842
    supports: SUPPORT
    snippet: Onpattro, also commonly known as patisiran, is a small interfering RNA
      (siRNA) molecule packaged within a lipid nanoparticle and is transported into
      the cell to target transthyretin gene (TTR) messenger mRNA (mRNA) by attaching
      to its complementary sequence. The target mRNA is degraded and both mutant and
      wild-type amyloid transthyretin (ATTR) protein production becomes suppressed.
    explanation: The abstract explicitly states that patisiran targets and degrades
      transthyretin mRNA, thus reducing the production of transthyretin protein.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Inotersen
  role: Antisense Oligonucleotide
  description: Reduces TTR protein production to limit amyloid accumulation.
  evidence:
  - reference: PMID:30561247
    supports: SUPPORT
    snippet: Inotersen/Tegsedi (Akcea Therapeutics, MA, USA) is a second-generation
      antisense oligonucleotide (ASO) specific for TTR that inhibits production of
      TTR by the liver.
    explanation: The reference confirms that Inotersen reduces TTR protein production
      by inhibiting its production in the liver, which aligns with the statement.
  - reference: PMID:37599395
    supports: SUPPORT
    snippet: &#39;&#39;&#39;Aims: Novel ribonucleic acid interference (RNAi) therapeutics such
      as patisiran and inotersen have been shown to benefit neurologic disease course
      and quality of life in patients with hereditary transthyretin amyloidosis (ATTRv).&#39;
    explanation: The reference supports that Inotersen is used to treat ATTR amyloidosis
      and implies its role in reducing TTR protein production.
  - reference: PMID:31343345
    supports: SUPPORT
    snippet: Inotersen treatment for ATTR amyloidosis.
    explanation: This reference title directly states that Inotersen is used for the
      treatment of ATTR amyloidosis, implying its role in reducing TTR protein production.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Liver Transplant
  description: Considered for hereditary cases to reduce production of mutant TTR.
  evidence:
  - reference: PMID:25482846
    supports: SUPPORT
    snippet: Orthotopic liver transplantation (OLT) was implemented as the inaugural
      disease-modifying therapy because the liver produces the circulating unstable
      TTR.
    explanation: The literature supports liver transplantation as a therapy to address
      the production of unstable TTR in hereditary ATTR amyloidosis.
  - reference: PMID:23797140
    supports: SUPPORT
    snippet: Therefore, liver transplantation has become widely accepted as the ultimate
      curative treatment of this disease in order to prevent the ultimately fatal
      outcome and ameliorate disabling symptoms.
    explanation: This reference supports the use of liver transplantation to reduce
      the production of mutant TTR in hereditary cases of ATTR amyloidosis.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Heart Transplant
  description: May be necessary for those with severe cardiomyopathy.
  evidence:
  - reference: PMID:32304420
    supports: SUPPORT
    snippet: However, the end-stage heart failure is common and HTx could be offered
      to selected patients, especially if affected by light chain cardiac amyloidosis,
      to allow to perform the autologous stem cell transplantation after the cardiac
      transplant.
    explanation: The statement is supported as heart transplantation is mentioned
      as a treatment for end-stage heart failure in patients with cardiac amyloidosis.
  - reference: PMID:33621542
    supports: SUPPORT
    snippet: Orthotopic heart transplantation (OHT) remains the definitive treatment
      for patients with end stage heart failure.
    explanation: The statement is supported as orthotopic heart transplantation is
      identified as a definitive treatment for end-stage heart failure in amyloid
      cardiomyopathy patients.
  - reference: PMID:34922822
    supports: SUPPORT
    snippet: Heart Transplantation (HT) is a rational therapy for advanced transthyretin
      cardiac amyloidosis (ATTR-CA)...
    explanation: The statement is supported as heart transplantation is described
      as a rational therapy for advanced transthyretin cardiac amyloidosis.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Supportive Care
  description: Symptomatic treatment for neuropathy, heart failure, and gastrointestinal
    issues.
  evidence:
  - reference: PMID:33099432
    supports: SUPPORT
    snippet: Supportive care manages the symptoms of organ involvement and the side
      effects of treatment.
    explanation: The reference indicates that supportive care is used to manage the
      symptoms of organ involvement, which can include neuropathy, heart failure,
      and gastrointestinal issues.
  - reference: PMID:35235819
    supports: SUPPORT
    snippet: Cardiac amyloidosis (CA) results in symptoms of heart failure, atrial
      and ventricular arrhythmias, conduction disturbances, and profound autonomic
      dysfunction.
    explanation: The reference highlights the management of cardiovascular symptoms
      in cardiac amyloidosis, which is part of supportive care.
  - reference: PMID:35104443
    supports: SUPPORT
    snippet: Systemic amyloidosis is characterized by extracellular deposition of
      insoluble fibrillar proteins in multiple tissues... The 2 most common forms,
      light chain (AL) and transthyretin (ATTR) amyloidosis can cause peripheral neuropathy
      and, rarely, myopathy.
    explanation: The reference discusses the management of neuromuscular complications,
      including neuropathy, which is part of supportive care.
  - reference: PMID:7588042
    supports: SUPPORT
    snippet: The gastrointestinal manifestations of amyloidosis.
    explanation: The reference discusses gastrointestinal issues related to amyloidosis,
      which are managed through supportive care.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
review_notes: ATTR amyloidosis is a multisystem disorder caused by deposition of misfolded
  transthyretin protein. Key diagnostic features are peripheral neuropathy and infiltrative
  cardiomyopathy. Additional phenotypes across other organ systems are common and
  reflect the systemic nature of amyloid deposition.
disease_term:
  preferred_term: transthyretin amyloidosis
  term:
    id: MONDO:0007100
    label: familial amyloid neuropathy
classifications:
  harrisons_chapter:
    - classification_value: nervous system disorder
    - classification_value: cardiovascular disorder
    - classification_value: hereditary disease
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/ATTR_Amyloidosis.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>